Skip to main content

Table 5 Subgroup analyses in the full analysis set

From: Open-label phase 3 study of diclofenac conjugated to hyaluronate (diclofenac etalhyaluronate: ONO-5704/SI-613) for treatment of osteoarthritis: 1-year follow-up

  Baseline
Mean ± SD
Week 2
Mean ± SD
Week 12
Mean ± SD
Week 24
Mean ± SD
Week 52
Mean ± SD
Patients with knee OA or other OA
 Knee OA (n) 126 126 122 121 120
 Pain score 6.0 ± 1.1 4.9 ± 2.0 4.5 ± 2.2 4.0 ± 2.4 3.1 ± 2.4
WOMAC score (mm)
 Pain 40.9 ± 18.7 33.1 ± 21.2 29.3 ± 22.3 26.7 ± 22.4 21.7 ± 22.1
 Stiffness 39.9 ± 25.9 32.2 ± 23.6 30.2 ± 24.5 28.2 ± 24.7 21.8 ± 22.6
 Function 40.5 ± 21.7 35.0 ± 23.0 29.4 ± 22.7 27.2 ± 23.7 22.0 ± 22.8
 Total 40.5 ± 20.2 34.4 ± 22.0 29.5 ± 22.3 27.2 ± 23.1 21.9 ± 22.3
 Other OA (n) 40 40 40 37 37
 Pain score 5.7 ± 1.3 4.7 ± 1.9 3.9 ± 2.2 3.6 ± 2.0 2.9 ± 2.3
Patients with or without analgesics for OA
 Usea (n) 135 135 132 129 128
 Pain score 5.9 ± 1.2 4.9 ± 1.9 4.3 ± 2.1 4.0 ± 2.2 3.2 ± 2.3
 Not usedb (n) 31 31 30 29 29
 Pain score 5.7 ± 1.2 4.7 ± 2.2 4.3 ± 2.4 3.7 ± 2.5 2.4 ± 2.4
  1. n number of patients in the subgroup, OA osteoarthritis, WOMAC Western Ontario and McMaster University Osteoarthritis 3.1 index
  2. aPatients who used analgesics for OA
  3. bPatients who did not use analgesics for OA